{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:22:15Z","timestamp":1761294135706,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00277-020-04126-y","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T19:02:36Z","timestamp":1591988556000},"page":"2133-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A multi-center retrospective analysis of patients with relapsed\/refractory follicular lymphoma after third-line chemotherapy"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Karasuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"issue":"6","key":"4126_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122(6):981\u2013987. https:\/\/doi.org\/10.1182\/blood-2013-03-491514","journal-title":"Blood"},{"issue":"23","key":"4126_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516\u20132522. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"issue":"4","key":"4126_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.15149","volume":"184","author":"BK Link","year":"2019","unstructured":"Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW (2019) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol 184(4):660\u2013663. https:\/\/doi.org\/10.1111\/bjh.15149","journal-title":"Br J Haematol"},{"issue":"5","key":"4126_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bjh.15708","volume":"184","author":"A Rivas-Delgado","year":"2019","unstructured":"Rivas-Delgado A, Magnano L, Moreno-Velazquez M, Garcia O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, Gonzalez-Farre B, Martinez A, Balague O, Delgado J, Villamor N, Gine E, Campo E, Sancho-Cia JM, Lopez-Guillermo A (2019) Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 184(5):753\u2013759. https:\/\/doi.org\/10.1111\/bjh.15708","journal-title":"Br J Haematol"},{"issue":"4","key":"4126_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.hoc.2019.03.003","volume":"33","author":"K Welaya","year":"2019","unstructured":"Welaya K, Casulo C (2019) Follicular lymphoma: redefining prognosis, current treatment options, and unmet needs. Hematol Oncol Clin North Am 33(4):627\u2013638. https:\/\/doi.org\/10.1016\/j.hoc.2019.03.003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"14","key":"4126_CR6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","volume":"133","author":"C Casulo","year":"2019","unstructured":"Casulo C, Barr PM (2019) How I treat early-relapsing follicular lymphoma. Blood 133(14):1540\u20131547. https:\/\/doi.org\/10.1182\/blood-2018-08-822148","journal-title":"Blood"},{"issue":"6","key":"4126_CR7","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sokler M, Dunzinger U, Nielsen T, Launonen A, Hiddemann W (2019) Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 104(6):1202\u20131208. https:\/\/doi.org\/10.3324\/haematol.2018.209015","journal-title":"Haematologica"},{"issue":"12","key":"4126_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JOP.2017.026336","volume":"13","author":"M Hamadani","year":"2017","unstructured":"Hamadani M, Horowitz MM (2017) Allogeneic transplantation for follicular lymphoma: does one size fit all? J Oncol Pract 13(12):798\u2013806. https:\/\/doi.org\/10.1200\/JOP.2017.026336","journal-title":"J Oncol Pract"},{"issue":"6","key":"4126_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41409-018-0372-5","volume":"54","author":"JE Norman","year":"2019","unstructured":"Norman JE, Schouten HC, Dreger P, Robinson SP (2019) The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies. Bone Marrow Transplant 54(6):787\u2013797. https:\/\/doi.org\/10.1038\/s41409-018-0372-5","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4126_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","volume":"14","author":"JM Vose","year":"2008","unstructured":"Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, Armitage JO (2008) Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 14(1):36\u201342. https:\/\/doi.org\/10.1016\/j.bbmt.2007.06.016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4126_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bjh.12741","volume":"165","author":"J Kothari","year":"2014","unstructured":"Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM (2014) Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Br J Haematol 165(3):334\u2013340. https:\/\/doi.org\/10.1111\/bjh.12741","journal-title":"Br J Haematol"},{"issue":"8","key":"4126_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/ajh.23246","volume":"87","author":"K Tada","year":"2012","unstructured":"Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, Tajima K, Mori S, Heike Y, Tanosaki R, Maeshima AM, Taniguchi H, Furuta K, Kagami Y, Matsuno Y, Tobinai K, Takaue Y, Fukuda T (2012) Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. Am J Hematol 87(8):770\u2013775. https:\/\/doi.org\/10.1002\/ajh.23246","journal-title":"Am J Hematol"},{"issue":"5","key":"4126_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bmt.2015.348","volume":"51","author":"F Heinzelmann","year":"2016","unstructured":"Heinzelmann F, Bethge W, Beelen DW, Engelhard M, Kroger N, Dreger P, Niederwieser D, Finke J, Bunjes D, Tischer J, Kobbe G, Holler E, Bornhauser M, Stelljes M, Baurmann H, Muller A, Haubitz I, Schrezenmeier H, Muller C, Ottinger H (2016) Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transplant 51(5):654\u2013662. https:\/\/doi.org\/10.1038\/bmt.2015.348","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4126_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/bmt.2015.223","volume":"51","author":"E Klyuchnikov","year":"2016","unstructured":"Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kroger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M (2016) Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant 51(1):58\u201366. https:\/\/doi.org\/10.1038\/bmt.2015.223","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4126_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC (2018) Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 124(8):1733\u20131742. https:\/\/doi.org\/10.1002\/cncr.31264","journal-title":"Cancer"},{"issue":"3","key":"4126_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4126_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1349-7006.2007.00662.x","volume":"99","author":"Y Oki","year":"2008","unstructured":"Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y (2008) Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Cancer Sci 99(1):179\u2013184. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00662.x","journal-title":"Cancer Sci"},{"issue":"9","key":"4126_CR18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","volume":"28","author":"C Casulo","year":"2017","unstructured":"Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR (2017) Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol 28(9):2094\u20132106. https:\/\/doi.org\/10.1093\/annonc\/mdx189","journal-title":"Ann Oncol"},{"issue":"9","key":"4126_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, Gerrie AS, Ferguson D, Cafferty F, Slack GW, Farinha P, Skinnider B, Connors JM, Sehn LH (2019) Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134(9):761\u2013764. https:\/\/doi.org\/10.1182\/blood.2019000258","journal-title":"Blood"},{"issue":"21","key":"4126_CR20","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/jco.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918\u20133927. https:\/\/doi.org\/10.1200\/jco.2003.10.023","journal-title":"J Clin Oncol"},{"issue":"7","key":"4126_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","volume":"17","author":"MR Tomblyn","year":"2011","unstructured":"Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG (2011) Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 17(7):1051\u20131057. https:\/\/doi.org\/10.1016\/j.bbmt.2010.11.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"4126_CR22","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25(17):2426\u20132433. https:\/\/doi.org\/10.1200\/JCO.2006.09.3260","journal-title":"J Clin Oncol"},{"issue":"14","key":"4126_CR23","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","volume":"29","author":"S Montoto","year":"2011","unstructured":"Montoto S, Fitzgibbon J (2011) Transformation of indolent B-cell lymphomas. J Clin Oncol 29(14):1827\u20131834. https:\/\/doi.org\/10.1200\/JCO.2010.32.7577","journal-title":"J Clin Oncol"},{"issue":"2","key":"4126_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/10428194.2016.1190975","volume":"58","author":"K Umino","year":"2017","unstructured":"Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y (2017) Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leuk Lymphoma 58(2):316\u2013323. https:\/\/doi.org\/10.1080\/10428194.2016.1190975","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4126_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128(8):1112\u20131120. https:\/\/doi.org\/10.1182\/blood-2016-05-717355","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04126-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T23:19:55Z","timestamp":1623453595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04126-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4126"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04126-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of the Osaka International Cancer Institute in Osaka, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}